We Offer Worldwide Shipping
Login Wishlist

Chrysanthemol

$1,030

  • Brand : BIOFRON

  • Catalogue Number : AV-C10165

  • Specification : 98%

  • CAS number : 113773-90-3

  • Formula : C15H26O2

  • Molecular Weight : 238.4

  • PUBCHEM ID : 11118126

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-C10165

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

238.4

Appearance

Powder

Botanical Source

Structure Type

Sesquiterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC12CCC(CC1C(=C)C(CC2)O)C(C)(C)O

Synonyms

2-Naphthalenemethanol, decahydro-7-hydroxy-α,α,4a-trimethyl-8-methylene-, (2R,4aS,7R,8aR)-/(2R,4aS,7R,8aR)-7-(2-Hydroxy-2-propanyl)-4a-methyl-1-methylenedecahydro-2-naphthalenol

IUPAC Name

(2R,4aS,7R,8aR)-7-(2-hydroxypropan-2-yl)-4a-methyl-1-methylidene-2,3,4,5,6,7,8,8a-octahydronaphthalen-2-ol

Density

1.0±0.1 g/cm3

Solubility

Quantitative RT-PCR, qRT-PCR, IBV, Infectious bronchitis virus

Flash Point

156.7±15.0 °C

Boiling Point

347.9±15.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C22H32O4/c1-22-11-10-18-17-7-5-16(25-13-23-2)12-15(17)4-6-19(18)20(22)8-9-21(22)26-14-24-3/h5,7,12,18-21H,4,6,8-11,13-14H2,1-3H3/t18-,19-,20-,21?,22+/m1/s1

InChl Key

ORTXDSRJUDCFHC-GEEQCMDESA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:113773-90-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31712094

Abstract

Infectious bronchitis (IB) is a highly contagious upper respiratory tract disease of chickens caused by infectious bronchitis virus (IBV), which has various serotypes that do not cross-protect. Vaccine control strategies for this virus are only effective when designed around the currently circulating serotypes. It is essential to not only rapidly detect IBV but also to identify the type of virus causing disease. Six TaqMan™-based quantitative real-time RT-PCR assays (Universal, Ark, Mass, DE/GA98, GA07, GA08) were developed and examined the sensitivity and specificity for each assay. Assays were developed targeting the hypervariable region in the S1 gene subunit. The analytical sensitivity of TaqMan™-based quantitative real-time RT-PCR assays (qRT-PCR) assays was evaluated using synthetic DNA standards that were identical with the target sequence and specificity was further validated using clinical and biological specimens. All developed assays performed equivalently when using synthetic DNA templates as standard material, as it achieved linearity over a 5 log10 dynamic range with a reproducible limit of detection of ≤10 target copies per reaction, with high calculated amplification efficiencies ranging between 90%-115%. Further validation of specificity using clinical and biological specimens was also successful.

KEYWORDS

Quantitative RT-PCR, qRT-PCR, IBV, Infectious bronchitis virus

Title

Validation of specific quantitative real-time RT-PCR assay panel for Infectious Bronchitis using synthetic DNA standards and clinical specimens

Author

Jongseo Mo,a Michael Angelichio,b Lisa Gow,b Valerie Leathers,b and Mark W. Jackwooda,*

Publish date

2020 Feb;

PMID

28531222

Abstract

Background
The World Health Organization (WHO) has targeted the elimination of Human African trypanosomiasis (HAT) ‘as a public health problem’ by 2020. The selected indicators of elimination should be monitored every two years, and we provide here a comprehensive update to 2014. The monitoring system is underpinned by the Atlas of HAT.

Results
With 3,797 reported cases in 2014, the corresponding milestone (5,000 cases) was surpassed, and the 2020 global target of ‘fewer than 2,000 reported cases per year’ seems within reach. The areas where HAT is still a public health problem (i.e. > 1 HAT reported case per 10,000 people per year) have halved in less than a decade, and in 2014 they corresponded to 350 thousand km2. The number and potential coverage of fixed health facilities offering diagnosis and treatment for HAT has expanded, and approximately 1,000 are now operating in 23 endemic countries. The observed trends are supported by sustained surveillance and improved reporting.

Discussion
HAT elimination appears to be on track. For gambiense HAT, still accounting for the vast majority of reported cases, progress continues unabated in a context of sustained intensity of screening activities. For rhodesiense HAT, a slow-down was observed in the last few years. Looking beyond the 2020 target, innovative tools and approaches will be increasingly needed. Coordination, through the WHO network for HAT elimination, will remain crucial to overcome the foreseeable and unforeseeable challenges that an elimination process will inevitably pose.

Title

Monitoring the elimination of human African trypanosomiasis: Update to 2014

Author

Jose R. Franco,#1,* Giuliano Cecchi,#2 Gerardo Priotto,1 Massimo Paone,3 Abdoulaye Diarra,4 Lise Grout,1 Raffaele C. Mattioli,3 and Daniel Argaw1

Publish date

2017 May

Title

Proceedings of the 22nd Annual Meeting of the Portuguese Society of Human Genetics

Publish date

2019 Jun;


Description :

Empty ...